Lilly partners with AC Immune for Alzheimer’s treatment

Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer’s disease.

Under the terms of the deal, AC Immune will receive an upfront payment of 80 million Swiss francs ($80.47 million) and $50 million in exchange for a note convertible to equity at a premium, the companies said on Wednesday.

https://www.reuters.com/article/us-lilly-alzheimers-ac-immune/lilly-partners-with-ac-immune-for-alzheimers-treatment-idUSKBN1OB18F